The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•16 April 2026•

1 min read

Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine

Key Facts

1Swissmedic approved VIMKUNYA (recombinant, adsorbed) for the prevention of chikungunya virus disease.

2The vaccine is approved for active immunization in individuals aged 12 years and above.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Added the official announcement date (April 16, 2026) and clarified the primary exchange listing and ticker (Nasdaq Copenhagen, OMX: BAVA).

Bavarian Nordic A/S officially announced on April 16, 2026, that it has secured regulatory approval from Swissmedic for its chikungunya vaccine, VIMKUNYA. The vaccine is indicated for active immunization against the chikungunya virus in individuals aged 12 years and older, marking a significant milestone for the company's European expansion. This approval follows successful clinical evaluations that validated the efficacy and safety of the recombinant vaccine. For investors, this regulatory milestone serves as a bullish catalyst, opening new revenue streams and validating the company's robust R&D pipeline. The company's stock is traded on Nasdaq Copenhagen under the ticker OMX: BAVA. Market analysts view this development as a positive driver for the company's valuation and long-term commercial prospects in the infectious disease sector.